Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

[1] Weber J(2009)A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma Clin Cancer Res 15 5591-5598

[2] Thompson JA(2010)Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol 11 155-164

[3] Hamid O(2010)Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711-723

[4] Minor D(2013)Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 122-133

[5] Amin A(2015)Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2521-2532

[6] Ron I(2016)Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Lancet 387 1540-1550

[7] Wolchok JD(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-135

[8] Neyns B(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 1627-1639

[9] Linette G(2016)Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet 387 1909-1920

[10] Negrier S(2015)PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma Oncotarget 6 3479-3492

[1] Weber J(2009)A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma Clin Cancer Res 15 5591-5598

[2] Thompson JA(2010)Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol 11 155-164

[3] Hamid O(2010)Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711-723

[4] Minor D(2013)Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 122-133

[5] Amin A(2015)Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2521-2532

[6] Ron I(2016)Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Lancet 387 1540-1550

[7] Wolchok JD(2015)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-135

[8] Neyns B(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 1627-1639

[9] Linette G(2016)Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet 387 1909-1920

[10] Negrier S(2015)PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma Oncotarget 6 3479-3492